SanBio (4592 JP): Remains Unlucky for Second-Time; Delay in First Product Approval Weighs Heavily
SanBio has deferred the approval timeline of its first product SB623 in Japan for the second time this year. The company expects SB623 approval is...
220 Views
SanBio (4592 JP): Marketing Approval of First Product Expected This Year in Japan
With promising clinical trial data and priority review status, SanBio’s lead drug candidate SB623 is expected to be approved in Japan this year....
660 Views
Ocumension Therapeutics IPO Initiation: Look into My Eyes
Ocumension Therapeutics (1764324D CH) is a China-based ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing...
478 Views
Japan - Shorts Cover as Market Rallies
The short notional in the market for the week ended 25 October is US$26.82bn (down by US$0.91bn) with the largest short positions in Itochu Corp...
434 Views
🇯🇵 JAPAN • Market Update - Levitating on Thin Air
MOVING AVERAGE BREAKOUT - Japanese equities have now risen by 5.1% since the low of 4th June and, since July 1st, the Total Market Value has...
601 Views